네오이뮨텍

950220KOSDAQSector: Pharma & Biotech

₩1,317▲ 1.31%Market cap ₩45.1BAs of Jul 21, 2026 close · updated once daily

Grade D38 ptsTop 74% of 2,523 stocks

Financial strength

36.8

Growth momentum

52.0

Price attractiveness

29.3

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

Financial strength

36.8

How much debt does it carry relative to equity?

Debt-to-equity ratio

38.6%

✓ Above median · Top 35.2% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

308.4%

✓ Above median · Top 33.9% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

-26596.6%

✗ Below median · Top 98.6% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

-54.2%

✗ Below median · Top 85.2% in sector

Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

Growth momentum

52.0

How much did revenue grow in a year?

Revenue growth (YoY)

-46.6%

✗ Below median · Top 94.7% in sector

Sector median 6.4%

Did core profits grow in a year?

Operating income change (YoY)

39.6%

✓ Above median · Top 23.9% in sector

Sector median 3.6%

Are core profits higher than three years ago?

Operating income change (3Y)

60.6%

✓ Above median · Top 25.5% in sector

Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

Price attractiveness

29.3

Is the price expensive relative to earnings?

P/E (price-to-earnings)

Loss-making (P/E not computable)

✓ Above median · Top 43.3% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

1111.11x

✗ Below median · Top 98.2% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15